UK markets closed

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
158.58+2.57 (+1.65%)
At close: 04:00PM EDT
158.36 -0.22 (-0.14%)
After hours: 04:54PM EDT
Sign in to post a message.
  • J
    Joe
    $SLS conversation
    For all the short tools, who work here - Hardly any real short volume left out there, only a loud lot of dead enders worried about getting squeezed and manipulative trading early and late, easy to see on the tape. Easy to do for a small bio. SLS will be launching. $jazz paid 1.5b for a lesser drug, 20M shares float, do the math.
  • j
    joe
    Bruce needs to buy Avadel now when they are vulnerable and the stock is trading in the $2s. Avadel's once nightly drug will kill the twice nightly market. It will launch no later than next year maybe even this year if they win a patent suit in August. I don't know why he hasn't made an offer yet. He pays $1.5B for Vyxeous that 5 yeas later only generates $134M. He's gonna lose $1B a year in SO sales when once nightly comes out so he should consider making a move now.
  • C
    Cured
    $SLS conversation
    FDA Green light to $800M in AML Revenue is SLS's True North
    - At what point will the market begin o appreciate your this multibillion dollar catalyst?
    PT $100 $2B in Market Cap based on the $Jazz comp. (article)

    New Presentation, confirms this multi billion dollar inflection point as soon 5 months unless the IDMC halts the 31 month P3 early for efficacy, as has been stated repeatedly by the Ceo.

    IMP: There are NO other drugs Even close to Gps, Not One in trial in all the NCT for AML CR2.
    Also as a Registrational Trial, REGAL the P3 has automatic FDA Approval triggers built in at Interim - 10 m of OS. which also triggers nearly $50M in 3D Med milestone money.
  • k
    kC
    $SLS conversation
    $XBI closed RED - $SLS Up Big and Green
    Divergency = a short emergency, 2 Massive Trial Results in 4 or 5 weeks and a Billion Dollar FDA Approval next year. SLS shares are Cheap As F - $50M Market cap when $jazz paid $1.5B for a direct comp, only a matter of time.
  • W
    Wren
    JAZZ looks like trash today - I bet it falls from here. Glad I am signed up to (http://Achieverspot.tech) so that I can get stocks that actually move!
  • J
    Joe
    $SLS conversation
    Massively undervalued Equity $Jazz paid $1.5B for Cpxx when it released its p3 data. SLS now trades for .0375 or 3.75% of what it will be worth when the AML Approval happens in 12 months no or sooner when the idmc halts the trial for efficacy.
  • J
    Joe
    $SLS conversation
    $Jazz paid $1.5B for Cpxx AML agent, similar to Gps P3 market. Equal to $75/sls share +2,770% ROI FDA approval 12 months If Idmc doesn’t halt this sooner.
  • Y
    You Should Know
    Is this the US govt owned stock where they use their patent on pot while making it still illegal for the competition? Yes, YES IT IS!
  • T
    The Gooch
    $SLS conversation
    $SLS is a slow bleed to zero. Buy $JAZZ.
  • T
    The Gooch
    $AVDL conversation
    Can $AVDL holder please stop spamming the $JAZZ boards now? I mean you all are eating a turd sandwich. Might as well keep your traps shut now that youll be out of business soon.
  • C
    CMOREGAINS
    Looking forward to tomorrows earnings report! This is currently one of my few stocks in the green (for now).
  • j
    joe
    I think Bruce will pony up the money! He was willing to pay $1.5 billion for Celator back in 2016 for their AML drug. The drug Vyxeos is only generating $134 million five years later. He pays $1.5 billion for a drug that makes him $135 million so what will he pay for a drug that will end up losing him over $1 billion if he doesn't wind up owning it?

    Like I said $8 is dirt cheap. I insult some here that think that is too low and the BoD won't accept that offer. OK he can up the ante and pay $750 million or $12 a share and he's still be getting a fantastic deal.

    He who gets ft218 will own the SO market for many years to come if they later produce a low sodium version.
  • L
    Larry
    got a serious question, what Bruce invented first the computer or the database?
  • T
    Tim
    Interesting Jazz is down $7 pre market. Very bizarre trading all ways around. Maybe a decision is imminent?
  • C
    CMOREGAINS
    So much for this being my only stock that "was" in the green.
  • A
    Adrien
    been holding for months and sold at 156. I feel I have missed something in my understanding on when to sell
  • k
    kC
    -----Extending Overall Survival from 5 months to 9.56 months of os is worth 1.5 B so what should the Sls drug be worth / In February 2020, SELLAS announced positive follow-up data from its Phase 2 study of GPS in CR2 AML patients. The final data showed a median overall survival (OS) of 21.0 months, at a median follow-up of 30.8 months, in patients receiving GPS compared to 5.4 months in patients treated with best standard care (p-value < 0.02). GPS therapy continued to be well tolerated throughout the study. /-/ Undervalued by 20x /Celator's $CPXX stock popped in March when it announced Vyxeos significantly improved overall survival in secondary AML patients (those w/ a previous malignancy) compared to the standard of care, from - 5.95 months, to 9.56 months - VS
    The final analysis GPs the SLS drug shows a median OS of 21 months in the GPS-treated patient cohort. Celator's stock shot up again at the end of May when $Jazz Pharmaceuticals announced it would buy the company for $1.5 billion, or about $30.25 per share, in cash.
    GPS Results are better 9.5 months of Survival for CPXX vs 21 months with GPs
  • j
    jim
    $SLS conversation
    1 Day First Hit (Reposting for vector-aka-dmanakajason) Expect a quadruple+ from upcoming Catalysts
    1. Pr announcing Annual Meeting is Now officially due
    2. Upside Earnings beat with Positive net income - 3 Days
    3. GLSI like Nps trial Results are imminent truly imminent - Any day now
    4. Gps Phase 3 Enrollment Complete announcement - Any day now
    5. Nps Out License - over due
    6. Gps Euro License - any day now
    7. More Milestone Money - March 12
    a quick list of known valuable catalysts
    Tiny float, No debt, Multi-billion and market comps. In the past couple of years, after valuable trial data was released the price would launch, shorts expected to cover with shares from an offering, so the price tanked -didn’t hold the value of real clinical data. That cycle is over - given the strong cash position $40M or so and microscopic burn rate of $3.5/4M quarter and the $202m licensee already paying.
    The earnings and cash pile announcement will motivate institutions to take a look at the Assets value. They will see $SLS currently trades at a huge discount to actual market comps. $jazz bought $cpxx for $1.5b when it extended survival to 5.95 months vs 21 months for Gps.
    $sls key drug Gps, extended survival to 21 months in the same exact patient setting.
    Yet this only trades for less than 8% of that?
    Gps treats 20 cancers in total.
    $200 per share this year on P3 Fda review
  • j
    jim
    $SLS conversation
    4 Days First HIt Reposting for vec and jay Could easily quadruple from the Upcoming Catalysts
    1. Pr announcing Annual Meeting is Now officially due
    2. Upside Earnings beat with Positive net income - 3 Days
    3. GLSI like Nps trial Results are imminent truly imminent - Any day now
    4. Gps Phase 3 Enrollment Complete announcement - Any day now
    5. Nps Out License - over due
    6. Gps Euro License - any day now
    7. More Milestone Money - March 12
    a quick list of known valuable catalysts
    Tiny float, No debt, Multi-billion and market comps. In the past couple of years, after valuable trial data was released the price would launch, shorts expected to cover with shares from an offering, so the price tanked -didn’t hold the value of real clinical data. That cycle is over - given the strong cash position $40M or so and microscopic burn rate of $3.5/4M quarter and the $202m licensee already paying.
    The earnings and cash pile announcement will motivate institutions to take a look at the Assets value. They will see $SLS currently trades at a huge discount to actual market comps. $jazz bought $cpxx for $1.5b when it extended survival to 5.95 months vs 21 months for Gps.
    $sls key drug Gps, extended survival to 21 months in the same exact patient setting.
    Yet this only trades for less than 8% of that?
    Gps treats 20 cancers in total.
    $200 per share this year on P3 Fda review
  • R
    Real Immuno Investor 10
    $SLS conversation
    Car T vectored Tcell drugs include significant side affects and costs - 400 -600K per patient ... Nps and Gps+ are off the shelf safe effective multivalent T Cell activators with proven durable anti cancer immunogenic ability preventing cancer recurrence For TNBC DCIS breast cancer patients and in Metastatic Active tumor Mesothelioma and Ovarian Cancer. And Increased survival by 400% from 5.95 months to 21 months for AML patients in end stage cancer. The drug that produced 5 months of survival in secondary remission patients was sold to $jazz for $1.5B - lastly packing it in, $SLS just picked up the first milestone payment from a $200m license, will be the reason for an upside Positive earnings surprise in the 10K.